Neurodevelopmental outcomes of infants after in utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine compared with unexposed infants: a COVI-PREG prospective cohort study.

Autor:	Favre G; Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland., Bromley RL; Division of Neuroscience, School of Biological Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, United Kingdom., Bluett-Duncan M; Division of Neuroscience, School of Biological Sciences, Faculty of Medicine, Biology and Health, University of Manchester, Manchester, United Kingdom., Maisonneuve E; Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland; Institute of Primary Health Care Berner Institut für Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland; Graduate School for Health Sciences (GHS), University of Bern, Bern, Switzerland., Pomar L; Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland; School of Health Sciences Haute Ecole de Santé Vaud (HESAV), University of Applied Sciences and Arts Western Switzerland, Lausanne, Switzerland., Daire C; Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland., Radan AP; Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland., Raio L; Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland., Surbek D; Department of Obstetrics and Fetal-Maternal Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland., Blume C; Kantonsspital Graubünden, Frauenklinik Fontana, Chur, Switzerland., Kalimeris S; Kantonsspital Graubünden, Frauenklinik Fontana, Chur, Switzerland., Madec Y; Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France., Schneider J; Clinic of Neonatology and Developmental Unit, Woman-Mother-Child Department, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Bickle Graz M; Clinic of Neonatology and Developmental Unit, Woman-Mother-Child Department, University Hospital Center and University of Lausanne, Lausanne, Switzerland., Winterfeld U; Swiss Teratogen Information Service, Clinical Pharmacology Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Panchaud A; Institute of Primary Health Care Berner Institut für Hausarztmedizin (BIHAM), University of Bern, Bern, Switzerland; Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland., Baud D; Materno-Fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital, Lausanne, Switzerland. Electronic address: david.baud@chuv.ch.
Jazyk:	angličtina
Zdroj:	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [Clin Microbiol Infect] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.
DOI:	10.1016/j.cmi.2024.10.019
Abstrakt:	Objectives: Data are lacking regarding the long-term consequences of SARS-CoV-2 and COVID-19 mRNA vaccine on infants exposed in utero. We aimed to evaluate the neurodevelopment of infants exposed prenatally to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy at 12 months after birth. Methods: Infants born to mothers exposed to SARS-CoV-2 or mRNA-COVID-19 vaccine during pregnancy, or unexposed to either the virus or the vaccine were enrolled from 2021 to 2023. Infants with prenatal exposure to the virus or vaccine were compared with infants without prenatal exposure to the virus and/or vaccine. Parents received a neurodevelopmental questionnaire (ages and stages questionnaire third edition) at 12 months after birth assessing five subdomains: communication, gross motor, fine motor, problem-solving, and personal social development. A low score was defined as <2 standard deviations below the normative mean in at least one of the subdomains. Results: A total of 330 infants were included (76 in the SARS-CoV-2 group, 153 in the mRNA-COVID-19 vaccine group, and 101 in the reference group). In utero exposure to the SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one subdomain compared with the reference group. The crude ORs were 1.16 (95% CI, 0.59-2.28) and 1.04 (95% CI, 0.58-1.86), respectively. Results remained consistent in the multivariate analysis, showing no increased risk of a low score for at least one subdomain for infants exposed to the SARS-CoV-2 or mRNA-COVID-19 vaccine, compared with the reference group. The adjusted ORs were 1.74 (95% CI, 0.76-3.99) and 0.76 (95% CI, 0.39-1.49), respectively. Discussion: In utero exposure to SARS-CoV-2 or mRNA-COVID-19 vaccine was not associated with an increased risk of a low score for at least one ages and stages questionnaire third edition subdomain at 12 months after birth. Additional studies are needed to confirm our results, especially longer-term evaluation of infant development. (Copyright © 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu